Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14060900 | 0.85 | ABCB1 (0.49) | LMNATSHRGAAKMT2AHPGD | |
| SCHEMBL202513 | 0.84 | NPC1 (0.51) | LMNATSHRHPGDHDAC1HDAC8 | |
| SCHEMBL13807290 | 0.84 | PTPN11 (0.45) | LMNATSHRGAAKMT2AHPGD | |
| SCHEMBL2225496 | 0.82 | HDAC1 (0.47) | LMNATSHRHDAC1HDAC8HDAC6 | |
| SCHEMBL203359 | 0.82 | HDAC1 (0.46) | HDAC1HDAC8HDAC6PTPN11NOTUM | |
| SCHEMBL6977195 | 0.82 | PTPN11 (0.44) | LMNATSHRGAAKMT2AHPGD | |
| SCHEMBL3070107 | 0.82 | PTPN11 (0.50) | LMNAPTPN11NPC1RAB9ADRD2 | |
| SCHEMBL2224843 | 0.82 | LMNA (0.59) | LMNATSHRGAAKMT2AHPGD | |
| SCHEMBL14294336 | 0.82 | LMNA (0.52) | LMNATSHRGAAKMT2AHPGD | |
| SCHEMBL2107712 | 0.82 | PTPN11 (0.47) | LMNATSHRGAAKMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111978268-A | 1- (4-chlorphenyl) -2-cyclopropyl acetone oxime oxazole methyl ether and application thereof | 湖南大学 | 2020-11-24 | — | — | CN | disclosed |
| WO-2015194954-A1 | 6,7-DIOXYALKYLTETRAHYDROISOQUINOLINE COMPOUNDS | STICHTING VOOR DE TECHNISCHE WETENSCHAPPEN (NL) | 2015-12-23 | — | — | WO | disclosed |
| EP-2533783-B1 | COMPOUNDS AND METHODS for the inhibition of HDAC | TEMPERO PHARMACEUTICALS INC (US) | 2015-11-04 | — | — | EP | disclosed |
| EP-2533783-B1 | COMPOUNDS AND METHODS for the inhibition of HDAC | TEMPERO PHARMACEUTICALS INC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-9095582-B2 | Substituted aryloxazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| US-9095582-B2 | Substituted aryloxazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| US-20150038534-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2015-02-05 | — | — | US | disclosed |
| US-20150038534-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2015-02-05 | — | — | US | disclosed |
| US-20150038534-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2015-02-05 | — | — | US | disclosed |
| US-8901156-B2 | Compounds and methods | TEMPERO PHARMACEUTICALS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-6624185-B2 | Drugs at least one lipid- or triglyceride-lowering active compound; and carriers for lipid metabolism | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-09-23 | — | — | US | disclosed |
| US-20030144332-A1 | Diarylcycloalkyl derivatives, processes for their preparation and their use s pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-07-31 | — | — | US | disclosed |
| WO-2003020269-A1 | DIARYL CYCLOALKYL DERIVATIVES, METHOD FOR PRODUCING THE SAME AND THE USE THEREOF AS PPAR ACTIVATORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-03-13 | — | — | WO | disclosed |
| CN-1356983-A | Tri-aryl acid derivatives as PPAR receptor ligands | AVENTIS PHARM PROD INC (DE) | 2002-07-03 | — | — | CN | disclosed |
| EP-1177176-A1 | TRI-ARYL ACID DERIVATIVES AS PPAR RECEPTOR LIGANDS | Aventis Pharma Deutschland GmbH (DE) | 2002-02-06 | — | — | EP | disclosed |
| WO-2000064876-A1 | TRI-ARYL ACID DERIVATIVES AS PPAR RECEPTOR LIGANDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-11-02 | — | — | WO | disclosed |
| EP-0628026-B1 | CYANO-OXIME ETHERS, PROCESS FOR PRODUCING THEM, AGENTS CONTAINING THEM AND THEIR USE | BASF AG (DE) | 1997-01-22 | — | — | EP | disclosed |
| EP-0628026-A1 | CYANO-OXIME ETHERS, PROCESS FOR PRODUCING THEM, AGENTS CONTAINING THEM AND THEIR USE. | BASF AG (DE) | 1994-12-14 | — | — | EP | disclosed |
| WO-1993016985-A1 | CYANO-OXIME ETHERS, PROCESS FOR PRODUCING THEM, AGENTS CONTAINING THEM AND THEIR USE | BASF AKTIENGESELLSCHAFT (DE) | 1993-09-02 | — | — | WO | disclosed |
| EP-0557834-A1 | Process for the preparation of heterocyclic aldehyds and ketones | BASF Aktiengesellschaft (DE) | 1993-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144332-A1 | Diarylcycloalkyl derivatives, processes for their preparation and their use s pharmaceuticals | PNLIP, LIPC, APOB | LMNA 1312/4885TSHR 1644/4885GAA 565/4885 |
| US-20150038534-A1 | COMPOUNDS AND METHODS | XDH, LPXN, CCNY | LMNA 26/4885TSHR 1016/4885GAA 1373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.